Abera Bioscience AB

Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.

ABERA | SPGR

Overview

Corporate Details

ISIN(s):: SE0015245097
LEI:: 549300IO3Q8IE2FDUS29
Country:: Sweden
Address:: BOX 1747, 751 47 Uppsala
Website:: https://aberabio.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Abera Bioscience AB is a vaccine development company focused on creating next-generation mucosal vaccines. The company utilizes its proprietary vaccine delivery platform, BERA, which is based on decorating Outer Membrane Vesicles (OMVs) with multiple antigens to stimulate a strong and broad immune response. Abera's pipeline includes vaccine candidates suitable for mucosal administration, such as nasal sprays. Its lead candidate is a universal pneumococcal vaccine preparing for clinical trials. The company also develops vaccine technologies for pandemic preparedness, leveraging over 30 years of experience in microbiological research to advance its innovative vaccine programs.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Abera Bioscience AB and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Abera Bioscience AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Abera Bioscience AB via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
2cureX AB Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.	Sweden	2CUREX
4BASEBIO PLC Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.	United Kingdom	4BB
4SC AG Developing small-molecule epigenetic drugs for high-need cancer indications.	Germany	VSC
ABINGDON HEALTH PLC A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.	United Kingdom	ABDX
ABIONYX Pharma Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.	France	ABNX
Abliva Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.	Sweden	ABLI
AB Science Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.	France	AB
Access Bio, Inc. Develops and manufactures rapid diagnostic tests for infectious diseases for global health.	United States of America	950130
Active Biotech Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.	Sweden	ACTI
AcuCort AB Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.	Sweden	ACUC